Azienda Ospedaliero-Universitaria Careggi (Aouc)

Florence 50134

1 studies enrolling now · 7 studies all time

What they study most

Anemia, B-Cell Malignancies, ET (Essential Thrombocythemia), MPN (Myeloproliferative Neoplasms), Multiple Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Neoplasms, Post-essential Thrombocythemia Myelofibrosis

Studies at this site

• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Recruiting now
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders — Running, not enrolling
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) — Completed
• To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma — Stopped early
• Entyvio (Vedolizumab) Long Term Safety Study — Completed